• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Lands' End Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

    8/31/23 12:50:39 PM ET
    $ACER
    $AGIL
    $ALLR
    $ASO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Professional Services
    Consumer Discretionary
    Get the next $ACER alert in real time by email

    Gainers

    • Acer Therapeutics Inc. (NASDAQ:ACER) shares jumped 145% to $1.4850 after Zevra Therapeutics announced it will acquire the company. The transaction will have a total potential value for Acer stockholders of up to $91 million.
    • 1847 Holdings LLC (NASDAQ:EFSH) surged 66.6% to $0.17. 1847 Holdings reported successful restructuring of promissory notes, with two institutional investors, totaling $1.75 million outstanding.
    • iCoreConnect Inc. (OTC:ICCT) climbed 51.7% to $18.63 after jumping 119% on Wednesday. Last Friday, the company announced theclosing of its previously announced business combination with FG Merger Corp., a special purpose acquisition corporation (SPAC).
    • Canopy Growth Corporation (NASDAQ:CGC) rose 31% to $0.59 after the HHS called for moving marijuana to a lower-risk drug category.
    • noco-noco Inc. (NASDAQ:NCNC) gained 30% to $2.08 after falling 20% on Wednesday.
    • Satixfy Communications Ltd. (NASDAQ:SATX) rose 27% to $0.6059 after the company announced a $60 million transaction with MDA.
    • Longeveron Inc. (NASDAQ:LGVN) shares gained 25.6% to $3.0669.
    • Upland Software, Inc. (NASDAQ:UPLD) gained 22% to $3.59.
    • Intrusion Inc. (NASDAQ:INTZ) rose 20% to $0.8485.
    • OpGen, Inc. (NASDAQ:OPGN) jumped 19.5% to $0.2091.
    • Microvast Holdings, Inc. (NASDAQ:MVST) rose 18.3% to $2.14 after Janney Montgomery Scott initiated coverage on the stock with a Buy rating and $8 price target.
    • cbdMD, Inc. (NASDAQ:YCBD) gained 17.5% to $1.21.
    • Cue Health Inc. (NASDAQ:HLTH) rose 17.4% to $0.5181. Tarsadia Investments sent a letter to board of Cue Health, Inc, calls on board to take immediate action to prevent further destruction of stockholder value.
    • Mesoblast Limited (NASDAQ:MESO) gained 16.5% to $1.6664 after the company reported better-than-expected FY23 EPS results. Additionally, Jefferies upgraded the stock from Hold to Buy.
    • Caleres, Inc. (NYSE:CAL) jumped 15.5% to $28.58 after the company reported mixed second-quarter earnings and reiterated 2023 guidance.
    • Ciena Corporation (NYSE:CIEN) gained 15% to $49.60 after the company reported upbeat third-quarter results.
    • Tilray Brands, Inc. (NASDAQ:TLRY) rose 14% to $3.03 after the HHS called for moving marijuana to a lower-risk drug category.
    • Okta, Inc. (NASDAQ:OKTA) shares surged 13% to $83.15 after the company reported better-than-expected second-quarter financial results and raised FY24 guidance above estimates.
    • 1-800-FLOWERS.COM, Inc. (NASDAQ:FLWS) gained 12.8% to $7.88 after the company reported mixed fourth-quarter results.
    • Moving iMage Technologies, Inc. (NYSE:MITQ) gained 12.5% to $0.9786.
    • Infinera Corporation (NASDAQ:INFN) jumped 12.2% to $4.7250.
    • Titan Machinery Inc. (NASDAQ:TITN) surged 11.6% to $32.46 after the company reported better-than-expected second-quarter results.
    • Academy Sports and Outdoors, Inc. (NASDAQ:ASO) gained 11.4% to $55.64 as the company reported a second-quarter FY23 sales decline of 6.2% year-on-year to $1.58 billion, in line with the analyst consensus estimate.
    • Genesco Inc. (NYSE:GCO) jumped 11% to $32.39 after the company reported better-than-expected second-quarter results.
    • CrowdStrike Holdings, Inc. (NASDAQ:CRWD) climbed 9.2% to $162.88 after the company reported better-than-expected second-quarter results and issued guidance above estimates.
    • Veeva Systems Inc. (NYSE:VEEV) gained 8.1% to $208.18 after the company reported a second-quarter earnings beat and issued guidance above estimates. Several analysts raised their price targets on the stock following the report.
    • Ollie's Bargain Outlet Holdings, Inc. (NASDAQ:OLLI) jumped 7.6% to $80.59 following strong quarterly results.
    • Allarity Therapeutics, Inc. (NASDAQ:ALLR) shares gained 6.8% to $1.7305. The company published clinical data in a peer-reviewed journal late Wednesday.

    Losers

    • Axcella Health Inc. (NASDAQ:AXLA) shares dipped 29.1% to $0.2701 after falling 15% on Wednesday.
    • AgileThought, Inc. (NASDAQ:AGIL) shares fell 27.7% to $0.2052 after jumping 83% on Wednesday.
    • SeqLL Inc. (NASDAQ:SQL) fell 23.1% to $15.07.
    • Lands' End, Inc. (NASDAQ:LE) declined 22.4% to $7.96 after the company reported worse-than-expected second-quarter results and issued weak guidance.
    • VCI Global Limited (NASDAQ:VCIG) tumbled 22% to $4.41.
    • GD Culture Group Limited (NASDAQ:GDC) fell 18% to $2.83.
    • OKYO Pharma Limited (NASDAQ:OKYO) fell 15.2% to $2.1212 after dipping 18% on Wednesday. The company announced that it has enrolled and randomized 90% of the patients in its 240-patient Phase 2 clinical trial of OK-101 to treat dry eye disease.
    • Starbox Group Holdings Ltd. (NASDAQ:STBX) dipped 15.2% to $2.45.
    • Dollar General Corporation (NYSE:DG) declined 14.8% to $134.33. Dollar General reported second-quarter FY23 sales growth of 3.9% year-on-year to $9.80 billion, missing the analyst consensus of $9.92 billion.
    • Duluth Holdings Inc. (NASDAQ:DLTH) dipped 13.6% to $6.34 after the company reported a year-over-year decrease in second-quarter EPS results and reiterated FY23 EPS guidance below estimates. Additionally, CFO Dave Loretta announced his decision to step down effective September 15.
    • JanOne Inc. (NASDAQ:JAN) fell 12.5% to $0.5379.
    • Hammerhead Energy Inc. (NASDAQ:HHRS) declined 12.2% to $11.05.
    • Polestar Automotive Holding UK PLC (NASDAQ:PSNY) dipped 11.7% to $3.3825 after the company missed second-quarter analyst estimates.
    • Digital Brands Group, Inc. (NASDAQ:DBGI) fell 11.6% to $10.06 after jumping 35% on Wednesday.
    • Chewy, Inc. (NYSE:CHWY) shares tumbled 10.1% to $24.58 following second-quarter results.
    • Top KingWin Ltd (NASDAQ:TCJH) shares fell 10% to $1.3501 after gaining 15% on Wednesday.
    • SIGNA Sports United N.V. (NYSE:SSU) dipped 8.7% to $1.15.
    • Beneficient (NASDAQ:BENF) fell 7.7% to $2.4750 after surging 28% on Wednesday.
    • World Wrestling Entertainment, Inc. (NYSE:WWE) fell 7.6% to $101.69.
    • Five Below, Inc. (NASDAQ:FIVE) shares fell 4.2% to $175.20. Five Below posted upbeat results for its second quarter, but issued weak outlook for the third quarter.

    Now Read This: Top 5 Risk Off Stocks That Are Ticking Portfolio Bombs

    Get the next $ACER alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACER
    $AGIL
    $ALLR
    $ASO

    CompanyDatePrice TargetRatingAnalyst
    OKYO Pharma Limited
    $OKYO
    2/20/2026$7.00Overweight
    Piper Sandler
    Polestar Automotive Holding UK PLC
    $PSNY
    2/19/2026Neutral → Underweight
    Cantor Fitzgerald
    Chewy Inc.
    $CHWY
    2/19/2026$28.00Mkt Perform → Outperform
    Raymond James
    Dollar General Corporation
    $DG
    2/17/2026$111.00Neutral → Sell
    Rothschild & Co Redburn
    Veeva Systems Inc.
    $VEEV
    2/17/2026$205.00Underweight → Equal-Weight
    Morgan Stanley
    CrowdStrike Holdings Inc.
    $CRWD
    2/13/2026$446.00Hold → Buy
    HSBC Securities
    Five Below Inc.
    $FIVE
    2/4/2026$233.00Underperform → Buy
    BofA Securities
    Tilray Brands Inc.
    $TLRY
    1/27/2026Hold
    Canaccord Genuity
    More analyst ratings

    $ACER
    $AGIL
    $ALLR
    $ASO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Mclean Andrew J. exercised 84,040 shares at a strike of $10.81 and covered exercise/tax liability with 63,072 shares, increasing direct ownership by 14% to 166,893 units (SEC Form 4)

    4 - LANDS' END, INC. (0000799288) (Issuer)

    2/19/26 4:00:03 PM ET
    $LE
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    SVP and Chief Strategy Officer Rothenstein David M sold $750,498 worth of shares (2,500 units at $300.20), decreasing direct ownership by 1% to 199,694 units (SEC Form 4)

    4 - CIENA CORP (0000936395) (Issuer)

    2/19/26 11:14:10 AM ET
    $CIEN
    Telecommunications Equipment
    Utilities

    President, CEO Smith Gary B sold $884,157 worth of shares (2,952 units at $299.51), decreasing direct ownership by 0.98% to 298,988 units (SEC Form 4)

    4 - CIENA CORP (0000936395) (Issuer)

    2/19/26 11:01:47 AM ET
    $CIEN
    Telecommunications Equipment
    Utilities

    $ACER
    $AGIL
    $ALLR
    $ASO
    SEC Filings

    View All

    SEC Form 6-K filed by OKYO Pharma Limited

    6-K - OKYO Pharma Ltd (0001849296) (Filer)

    2/23/26 11:00:27 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Mesoblast Limited

    6-K - MESOBLAST LTD (0001345099) (Filer)

    2/23/26 6:06:01 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)

    2/19/26 8:00:48 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACER
    $AGIL
    $ALLR
    $ASO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 14, 2023 - FDA Warns Nine Manufacturers, Distributors of Unapproved Antimicrobials for Animals

    For Immediate Release: December 14, 2023 Today, the U.S. Food and Drug Administration is announcing the issuance of nine warning letters to manufacturers and distributors of unapproved and misbranded antimicrobial animal drugs for violations of federal law. The agency is concerned because these products contain antimicrobials that are important in human medicine and using them without medical oversight contribut

    12/14/23 9:00:20 AM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    FDA Approval for OLPRUVA issued to ACER THERAPEUTICS INC

    Submission status for ACER THERAPEUTICS INC's drug OLPRUVA (ORIG-1) with active ingredient SODIUM PHENYLBUTYRATE has changed to 'Approval' on 12/22/2022. Application Category: NDA, Application Number: 214860, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/23/22 1:58:04 PM ET
    $ACER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACER
    $AGIL
    $ALLR
    $ASO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on OKYO Pharma with a new price target

    Piper Sandler initiated coverage of OKYO Pharma with a rating of Overweight and set a new price target of $7.00

    2/20/26 8:25:04 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Polestar Automotive Holding UK PLC downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Polestar Automotive Holding UK PLC from Neutral to Underweight

    2/19/26 7:50:28 AM ET
    $PSNY
    Auto Manufacturing
    Industrials

    Chewy upgraded by Raymond James with a new price target

    Raymond James upgraded Chewy from Mkt Perform to Outperform and set a new price target of $28.00

    2/19/26 7:46:41 AM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    $ACER
    $AGIL
    $ALLR
    $ASO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Scott Anthony bought $2,126 worth of shares (2,175 units at $0.98), increasing direct ownership by 0.34% to 638,793 units (SEC Form 4)

    4 - INTRUSION INC (0000736012) (Issuer)

    1/12/26 7:57:35 AM ET
    $INTZ
    Computer Communications Equipment
    Telecommunications

    Chief Financial Officer Pinson Kimberly bought $2,444 worth of shares (2,500 units at $0.98), increasing direct ownership by 4% to 61,154 units (SEC Form 4)

    4 - INTRUSION INC (0000736012) (Issuer)

    1/12/26 7:58:01 AM ET
    $INTZ
    Computer Communications Equipment
    Telecommunications

    SVP, Product Dev. & Sourcing Schlecht Richard W bought $62,394 worth of Class B Common Stock (28,554 units at $2.19), increasing direct ownership by 9% to 352,233 units (SEC Form 4)

    4 - DULUTH HOLDINGS INC. (0001649744) (Issuer)

    12/29/25 4:20:34 PM ET
    $DLTH
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    $ACER
    $AGIL
    $ALLR
    $ASO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress

    LONDON and NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that its abstract has been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting, taking place May 3-7, 2026, in Denver, Colorado. Chief Scientific Officer Raj Patil, Ph.D., will share the data in a presentation titled: "First-in-Human Study of Urcosimod to Treat Neuropathic Corneal Pain (NCP) Shows Clinically Meaningful Pain Reduction and Quality-of-Life Improve

    2/23/26 11:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    VCI Global Advances AI-Native Infrastructure Strategy with Formation of ROBODAX, Unifying Robotics Automation and Real-World Asset Digital Infrastructure

    KUALA LUMPUR, Malaysia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- VCI Global Limited (NASDAQ:VCIG) ("VCI Global" or the "Company") today announced the formation of ROBODAX, a strategic platform initiative established to unify the Company's robotics automation roadmap and real-world asset ("RWA") digital infrastructure strategy under a single execution architecture. The formation of ROBODAX marks a structural step in VCI Global's transition toward an AI-native infrastructure operating model. The initiative is designed to integrate robotics automation, AI orchestration frameworks, tokenisation architecture, and enterprise settlement capabilities into a coordinated platform strategy aimed at enablin

    2/20/26 8:24:00 AM ET
    $VCIG
    Diversified Commercial Services
    Consumer Discretionary

    Mesoblast Financial Results and Corporate Update Webcast

    NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the half year ended December 31, 2025. The webcast will begin at 5.00pm EST, Thursday, February 26; 9.00am AEDT, Friday, February 27, 2026. It can be accessed via: https://webcast.openbriefing.com/msb-hyr-2026/ The archived webcast will be available on the Investor page of the Company's website: www.mesoblast.com About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of

    2/20/26 7:00:00 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACER
    $AGIL
    $ALLR
    $ASO
    Leadership Updates

    Live Leadership Updates

    View All

    Polestar starts largest model offensive in its history: four new cars in three years

    Polestar 5 to start deliveries in summer, followed by a new variant of Polestar 4 in Q4 of 2026 Completely new successor of the iconic Polestar 2 in 2027 and compact SUV Polestar 7 in 2028 Michael Lohscheller, Polestar CEO: "Polestar continues to challenge the automotive industry, now by entering fast-growing and high value segments in record speed." Polestar (NASDAQ:PSNY) today announced the largest model offensive in its history, with four new cars planned in the next three years. The Company also announced that with a disciplined approach, in 2026 it expects low double-digit volume growth and a continued retail network expansion of 30%. This press release features multimedia.

    2/18/26 6:00:00 AM ET
    $PSNY
    Auto Manufacturing
    Industrials

    Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

    Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborationsCorporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue his work in the Company's on-going business development activities MIAMI, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerati

    2/13/26 4:30:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer

    Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal diseaseDr. Mantelli will lead the clinical and regulatory strategy to advance the company's development program in neuropathic corneal pain (NCP), leveraging urcosimod's FDA Fast Track designationThis appointment, following the recent CEO appointment, further strengthens OKYO's world-class ophthalmology leadership team LONDON and NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neur

    2/10/26 8:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACER
    $AGIL
    $ALLR
    $ASO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by iCoreConnect Inc.

    SC 13G/A - iCoreConnect Inc. (0001906133) (Subject)

    12/12/24 9:44:00 PM ET
    $ICCT
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G filed by VCI Global Limited

    SC 13G - VCI Global Ltd (0001930510) (Subject)

    12/6/24 6:01:22 AM ET
    $VCIG
    Diversified Commercial Services
    Consumer Discretionary

    $ACER
    $AGIL
    $ALLR
    $ASO
    Financials

    Live finance-specific insights

    View All

    Genesco to Report Fourth Quarter Fiscal 2026 Financial Results and Hold Conference Call on March 6, 2026

    Genesco Inc. (NYSE:GCO) today announced that the Company will report financial results for the fourth quarter fiscal 2026 on March 6, 2026, before the market opens, and hold its quarterly earnings conference call at 7:30 a.m. (Central time) the same day. A live audio webcast of the conference call will be available at https://www.genesco.com/investor-relations/investor-overview An audio archive of the call will be available for up to one year at https://www.genesco.com/investor-relations/investor-overview In addition, a summary of the fourth quarter fiscal 2026 results will be available on the Genesco website on March 6, 2026 at https://www.genesco.com/investor-relations/investor-o

    2/18/26 4:30:00 PM ET
    $GCO
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Beneficient Reports Third Quarter Fiscal 2026 Results

    DALLAS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ:BENF) ("Ben" or the "Company"), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets, today reported its financial results for the fiscal 2026 third quarter, which ended December 31, 2025. Highlights of the quarter include: Resolved GWG Holdings, Inc. litigation and regained Nasdaq complianceGenerated $50 million in gross proceeds from asset salesFully paid off HH-BDH Credit Agreement principal balance (excluding $1.7 million for deferred interest and fees)Strengthened balance sheet and collateral base Commenting on the

    2/17/26 5:00:00 PM ET
    $BENF
    Finance: Consumer Services
    Finance

    cbdMD Reports Sequential Revenue Growth, Improved Liquidity, and Strong Start to Fiscal 2026

    CHARLOTTE, N.C., Feb. 17, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD, Bluebird Botanicals, Paw CBD, along with its THC beverage brand Oasis today announced its financial results for the first quarter of fiscal year ended December 31, 2025. cbdMD reported 12% sequential revenue growth and improved liquidity in the first quarter of fiscal 2026, reflecting continued stabilization of the core business and early benefits from recent strategic actions."We a

    2/17/26 4:10:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary